Ziopharm Oncology Inc. (NASDAQ:ZIOP) shares saw an uptick in trading volume on Friday . 7,719,234 shares changed hands during mid-day trading, an increase of 189% from the previous session’s volume of 2,666,586 shares.The stock last traded at $4.92 and had previously closed at $5.67.

Several research firms recently weighed in on ZIOP. Wells Fargo & Co. reiterated an “underperform” rating on shares of Ziopharm Oncology in a report on Friday. Griffin Securities reiterated a “buy” rating and issued a $21.00 target price on shares of Ziopharm Oncology in a report on Friday, July 1st. Raymond James Financial Inc. began coverage on shares of Ziopharm Oncology in a report on Thursday, June 2nd. They issued a “market perform” rating for the company. Zacks Investment Research downgraded shares of Ziopharm Oncology from a “buy” rating to a “hold” rating in a report on Tuesday, May 31st. Finally, Mizuho lifted their target price on shares of Ziopharm Oncology from $6.00 to $7.00 and gave the company a “neutral” rating in a report on Wednesday, May 11th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $11.07.

The firm’s market capitalization is $652.38 million. The company’s 50-day moving average is $6.34 and its 200 day moving average is $7.01.

Ziopharm Oncology (NASDAQ:ZIOP) last announced its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by $0.01. During the same quarter in the prior year, the company earned ($0.69) earnings per share. The firm had revenue of $1.97 million for the quarter, compared to the consensus estimate of $1.89 million. Ziopharm Oncology’s revenue was up 623.9% on a year-over-year basis. Equities analysts forecast that Ziopharm Oncology Inc. will post ($0.42) earnings per share for the current fiscal year.

Several hedge funds and institutional investors have recently made changes to their positions in the company. Swiss National Bank boosted its position in shares of Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock valued at $1,323,000 after buying an additional 3,500 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Ziopharm Oncology by 18.4% in the fourth quarter. Wells Fargo & Company MN now owns 168,616 shares of the biotechnology company’s stock valued at $1,402,000 after buying an additional 26,233 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Ziopharm Oncology by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 212,521 shares of the biotechnology company’s stock valued at $1,766,000 after buying an additional 3,354 shares during the last quarter. California Public Employees Retirement System boosted its position in shares of Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock valued at $2,554,000 after buying an additional 261,300 shares during the last quarter. Finally, Morgan Stanley boosted its position in shares of Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock valued at $13,447,000 after buying an additional 78,583 shares during the last quarter.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.